Cardiovascular risk in uremic patients: darkness after AURORA

Ren Fail. 2010 Jan;32(2):269-72. doi: 10.3109/08860221003602652.
No abstract available

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases / prevention & control*
  • Data Interpretation, Statistical
  • Fluorobenzenes / adverse effects
  • Fluorobenzenes / therapeutic use*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Kidney Failure, Chronic / blood
  • Kidney Failure, Chronic / drug therapy*
  • Kidney Failure, Chronic / mortality
  • Lipids / blood
  • Patient Dropouts / statistics & numerical data
  • Patient Selection
  • Pyrimidines / adverse effects
  • Pyrimidines / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Renal Dialysis / adverse effects*
  • Research Design
  • Risk
  • Rosuvastatin Calcium
  • Sulfonamides / adverse effects
  • Sulfonamides / therapeutic use*
  • Uremia / blood
  • Uremia / drug therapy*
  • Uremia / mortality

Substances

  • Fluorobenzenes
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipids
  • Pyrimidines
  • Sulfonamides
  • Rosuvastatin Calcium